Clinical trials: Pancreatic Cancer Stage
Tumors, Ovarian Cancer
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant…
- Conditions
- Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT05431582
- Testing
- ZN-c3, Bevacizumab, Pembrolizumab
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas.
- Trial name
- TART (NCT00735306)
- Testing
- Avastin, Tarceva, Radiation Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Duke University
Pancreatic Cancer
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
The goal of this clinical research study is to learn if a chemotherapy combination called modified Folfirinox (or mFolfirinox), followed by a combination of gemcitabine and radiation therapy, followed by surgery, can help to…
- Trial name
- NCT01560949
- Testing
- Oxaliplatin, Irinotecan, 5-FU
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07435038
- Testing
- BPI-572270
- Where
- 7 sites in Australia, China
- Volunteers
- 120 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Pancreatic Cancer
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112658
- Testing
- fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 55 sites in France
- Volunteers
- 342 people
- Sponsor
- UNICANCER
Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
PULSAR in Systemic Therapy for Pancreatic Cancer
Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07269626
- Testing
- Personalized Ultrafractionated Adaptive Radiotherapy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samsung Medical Center
Pancreatic Cancer
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.
- Trial name
- NCT02672917
- Testing
- MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- BioNTech Research & Development, Inc.
Metastatic Pancreatic Cancer
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
The primary objective of this study is to compare the overall survival of patients with stage IV pancreatic cancer treated with gemcitabine alone or gemcitabine with bavituximab.
- Trial name
- NCT01272791
- Testing
- bavituximab, Gemcitabine
- Where
- 19 sites in United States, Ukraine
- Volunteers
- 70 people
- Sponsor
- Peregrine Pharmaceuticals
Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
This is a Phase I safety and feasibility study. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed one cycle of therapy (28 days) before the next subject can be treated.
- Trial name
- NCT01897415
- Testing
- Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective when given alone or in combination with another…
- Trial name
- NCT00012220
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 259 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.
- Trial name
- NCT07175389
- Testing
- JDB153, Serplulimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Locally Advanced Pancreatic Cancer
Pancreatic Locally Advanced Irresectable Cancer Ablation
The aim of the PELICAN trial is to investigate the survival benefit of RFA plus standard palliative chemotherapy as compared to palliative chemotherapy alone in patients with LAPC after 2 months of induction chemotherapy.
- Trial name
- PELICAN (NCT03690323)
- Testing
- Radiofrequency ablation (RFA), FOLFIRINOX, Nab-paclitaxel plus Gemcitabine
- Where
- 2 sites in Netherlands
- Volunteers
- 228 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer, Adenocarcinoma of the Pancreas
Switch Maintenance in Pancreatic
This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body.
- Conditions
- Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
- Trial name
- NCT05419479
- Testing
- ZIMBERELIMAB, DOMVANALIMAB, APX005M
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- James Cleary, MD, PhD
Pancreatic Cancer
Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as mitomycin C and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PACT-11 (NCT00967291)
- Testing
- ifosfamide, mitomycin C
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Adenocarcinoma, Pancreatic Cysts
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
This multicenter randomized trial aims to primarily assess and compare the functional recovery of patients who undergo open versus robotic pancreaticoduodenectomy for benign and malignant lesions of the head of the pancreas.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cysts, Pancreatic Endocrine Tumors, Chronic Pancreatitis
- Trial name
- PORTAL (NCT04400357)
- Testing
- Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer, Pancreatic Cancer
EGF Ointment for Erlotinib Skin Lesion
Epidermal growth factor receptor-tyrosin kinase inhibitor (EGFR-TKI, Erlotinib) has demonstrated its efficacy in patients with non-small cell lung cancer and pancreatic cancer.
- Trial name
- NCT01593995
- Testing
- Epidermal growth factor (EGF) ointment
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Dong-A University Hospital
Pancreatic Cancer
Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic…
- Trial name
- NCT00032175
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- 30 sites in United Kingdom
- Volunteers
- 508 people
- Sponsor
- Cancer Research UK
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Advanced Pancreatic Cancer
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
This is a Phase Ib/II study to evaluate the safety, tolerability and efficacy of IBI343 in combination with chemotherapy in patients with advanced pancreatic cancer, including a Phase Ib safety introduction and Phase II expansion…
- Trial name
- NCT07692750
- Testing
- IBI343+ capecitabine, IBI343+Capecitabine+oxaliplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.